Neovasc (NVCN) Trading 5% Higher

Neovasc Inc (NASDAQ:NVCN) (TSE:NVC)’s share price traded up 5% on Wednesday . The stock traded as high as $0.64 and last traded at $0.63. 971,101 shares changed hands during trading, a decline of 16% from the average session volume of 1,152,250 shares. The stock had previously closed at $0.60.

A number of research firms have recently commented on NVCN. ValuEngine raised Neovasc from a “hold” rating to a “buy” rating in a report on Wednesday, January 2nd. Zacks Investment Research raised Neovasc from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Wednesday, November 21st.

The firm has a market capitalization of $14.84 million, a P/E ratio of -0.02 and a beta of 1.59.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last posted its quarterly earnings results on Wednesday, November 14th. The medical equipment provider reported ($0.61) EPS for the quarter. The firm had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.47 million. On average, equities research analysts anticipate that Neovasc Inc will post -1.4 EPS for the current fiscal year.

An institutional investor recently bought a new position in Neovasc stock. Capital Research Global Investors acquired a new position in Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 704,769 shares of the medical equipment provider’s stock, valued at approximately $1,917,000. Capital Research Global Investors owned approximately 3.62% of Neovasc as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 16.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Neovasc (NVCN) Trading 5% Higher” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

Neovasc Company Profile (NASDAQ:NVCN)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Further Reading: What are no-load funds?

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.

Leave a Reply